Immunobiology of the Tomatine adjuvant

Vaccine

Volumn 22, Issue 19, 2004, Pages 2380-2384

  Morrow, W J W ^a   Yang, Y W ^b   Sheikh, N A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Adjuvant; Antigen processing; Cytotoxic T lymphocytes; Gel dispersion matrix; Glycoalkaloid; Tomatine

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; B7 ANTIGEN; BACTERIAL PROTEIN; CD86 ANTIGEN; CIRCUMSPOROZOITE PROTEIN; FREUND ADJUVANT; GLYCOLIPID; ISCOM; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; PROTEIN; PROTOZOAL PROTEIN; PROVAX; QUIL A; SAPONIN; TOMATINE;

ANTIBODY TITER; ANTIGEN SPECIFICITY; CANCER; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; FRANCISELLA TULARENSIS; HUMORAL IMMUNITY; IMMUNOBIOLOGY; LYMPH NODE; MACROPHAGE; MALARIA; NONHUMAN; PRIORITY JOURNAL; TULAREMIA; TUMOR REGRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; MALARIA VACCINES; T-LYMPHOCYTES, CYTOTOXIC; TOMATINE; VACCINATION;

EID: 2942562262     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.022     Document Type: Conference Paper

References (22)

1. Liu M.A. Vaccine developments. Nat Med. 4(Suppl):1998;515-519
2. Raychaudhuri S., Morrow W.J.W. Can soluble antigens induce MHC class I restricted immune responses? A paradox revisited. Immunol. Today. 14:1993;344-348
3. Sheikh N., Rajananthanan P., Morrow W.J.W. Immunological adjuvants: mechanisms of action and clinical applications. Expert Opin. Investigation. Drugs. 5:1996;1079-1099
4. Sheikh N.A., Al-Shamisi M., Morrow W.J.W. Delivery systems for molecular vaccination. Curr. Opin. Mol. Therap. 2:2000;37-54
5. Keukens E.A., de Vrije T., Fabrie C.H., Demel R.A., Jongen W.M., de Kruijff B. Dual specificity of sterol-mediated glycoalkaloid induced membrane disruption. Biochim. Biophys. Acta. 1110:1992;127-136
6. Keukens E.A., de Vrije T., van den Boom C., de Waard P., Plasman Thiel F., Chupin V., et al. Molecular basis of glycoalkaloid induced membrane disruption. Biochim. Biophys. Acta. 1240:1995;216-218
7. Keukens E.A., de Vrije T., Jansen L.A., de Boer H., Janssen M., de Krron A.I., et al. GLycoalkaloids selectively permeabilize cholesterol containing membranes. Biochim. Biophys. Acta. 1279:1996;243-250
8. Espinet R.G. Noveau vaccine antiaphteux a complexe glucoviral. Gac. Vet. 13:1951;268-270
9. Hyslop N.St.G., Morrow A.W. The influence of aluminium hydroxide content, dose, volume and the inclusion of saponins on the efficacy of inactivated foot-and-mouth vaccines. Res. Vet. Sci. 10:1969;109-120
10. Kensil C.R., Wu J.Y., Anderson C.A., Wheeler D.A., Amsden J. QS-21 and QS-7: purified saponin adjuvants. Dev. Biol. Stand. 92:1998;41-47
11. Rick C.M., Uhlig J.W., Jones A.D. High alpha-tomatine content in ripe fruit of Andean Lycopersicon esculentum var. cerasiforme: developmental and genetic aspects. Proc Natl Acad Sci U.S.A. 91:1994;12877-12881
12. Yang Y.-W., Sheikh N.A., Morrow W.J.W. The ultrastructure of tomatine adjuvant. Biomaterials. 23:2002;4677-4686
13. Rajananthanan P., Sheikh N.A., Attard G.S., Morrow W.J.W. Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses. Vaccine. 17:1999;715-730
14. Sheikh N.A., Rajananthanan P., Attard G.S., Morrow W.J.W. Generation of antigen-specific CD8+ cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants. Vaccine. 17:1999;2974-2982
15. Sheikh N.A., Attard G.S., van Rooijen N., Rajananthanan P., Hariharan K., Yang Y.-W., et al. Differential requirements for CTL generation by novel immunostimulants: APC tropism, use of the TAP-independent processing pathway and dependency on CD80/86 co-stimulation. Vaccine. 21:2003;3775-3788
16. Rajananthanan P., Attard G.S., Sheikh N.A., Morrow W.J.W. Novel aggregate structure adjuvants modulate Th1 and Th2 cytokine profiles in immunized mice. Vaccine. 18:1999;140-152
17. Heal K.G., Sheikh N.A., Hollingdale M.R., Morrow W.J.W., Taylor-Robinson A.W. Potentiation by a novel alkaloid glycoside adjuvant of a protective cytotoxic T cell immune response specific for a preerythrocytic malaria vaccine candidate antigen. Vaccine. 19:2001;4153-4161
18. Taylor-Robinson A.W., Morrow W.J.W. Tomatine as an adjuvant in malaria vaccine development. Drugs Future. 27:2002;391-401. Published online at http://www.prous.com/journals/dof/advpublication/index.cfm
19. Rajananthanan P, Sheikh NA, Attard GS, Souberbielle B, Morrow WJW. Cancer vaccine design: a novel glycoside adjuvant induces CD8+ cytotoxic T cell mediated tumor regression and increased survival in a murine model system. Cancer Immunol Immunother [in press].
20. Raychaudhuri S., Tonks M., Carbone F., Ryskamp T., Morrow W.J., Hanna N. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci U.S.A. 89:1992;8308-8312
21. Yang Y-W, Wu C-A, Morrow WJW. The apoptotic and necrotic effects of tomatine adjuvant. Vaccine 2004;22:2316-27.
22. Morrow W.J.W., Sheikh N.A. Guns genes and spleen: a coming of age for rational vaccine design. Methods. 31:2003;183-192